Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Blackhawk Growth Corp C.BLR

Alternate Symbol(s):  C.BLR.WT | BLRZF

Blackhawk Growth Corp. is a Canada-based investment holding company. The Company invests in equity and debt instruments of companies to generate positive returns for shareholders. It focuses on investing in multiple companies across a variety of sectors across North America. The Company has focused its investments on the health, cannabis and cannabidiol (CBD) industries, in both Canada and the United States.


CSE:BLR - Post by User

Post by Loonyon Sep 01, 2024 8:55pm
518 Views
Post# 36204937

Psychedelics: CEOs 15k Retreats or Justin's Take-Home?

Psychedelics: CEOs 15k Retreats or Justin's Take-Home?https://www.tricycleday.com/p/hate-say-microdosers-told

Return on investment: CEOs are spending $15k on mushroom retreats to become better leaders.

Here's why microdosing advocates are having their "I told you so" moment.

•  Results that last: Three months after an 8-week LSD microdosing treatment, patients still showed a 62.8% reduction in depressive symptoms. (That’s not a typo, folks.)

•  You can take it with you: Unlike other psychedelic pharma treatments, MindBio's approach lets patients self-administer at home. No tripsitter necessary.

•  Ease of use: The trial showed "excellent safety, adherence, and tolerance." In human speak? Microdosing didn’t cause people problems, so they actually stuck with it.

•  Budget friendly: CEO Justin Hanka claims this could be a "globally scalable, effective, affordable way to treat patients." (Gotta be cheaper than sitting with 2 therapists for 8 hours, right?)
<< Previous
Bullboard Posts
Next >>